The Oncology Institute of Hope and Innovation Open Clinical Trial June 2015

June 22, 2015 - PRLog -- The Oncology Institute of Hope and Innovation is proud to have access to the latest research, technology and treatment options, including clinical trials for eligible patients. We are dedicated to providing comprehensive medical services to our patients.  In our quest to be at the forefront of the latest medical cancer research, we participate in numerous clinical trials focused on various types of malignancies that may be of interest to your oncology patients.  We are pleased to announce the opening of the following clinical trial which may benefit some of your patients with Non-Hodgkin Lymphoma

         This is a  Phase 2, open-label, single arm  efficacy and safety study of IPI-145 administered orally to subjects diagnosed with indolent Non-Hodkins Lymphoma whose disease is refractory to rituximab and to either chemotherapy or RIT

         The primary objective of this study is to evaluate the antitumor activity of IPI-145 administered to subjects diagnosed with indolent Non-Hodgkin Lymphoma, whose disease is refractory to Rituximab and to either chemotherapy or radioimmunotherapy

       If you have patients who you feel may qualify for this trial, or have questions regarding eligibility, please contact any one of our offices listed below to schedule an evaluation.  We look forward to working with you.

Please contact (562) 869-1201 if you or your patient is interested in signing up